After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients
2nd January 2025 Uncategorised 0More than three years after Novartis’ plan for a speedy approval for its intrathecal Zolgensma was thwarted by an FDA requirement for a phase 3 trial, the company is back with a positive readout from that study, which could give the gene therapy a much-needed boost.
More: After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients
Source: fierce